We've found
35,033
archived clinical trials in
Lung Cancer
We've found
35,033
archived clinical trials in
Lung Cancer
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Click here to add this to my saved trials

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Click here to add this to my saved trials

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Click here to add this to my saved trials

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Click here to add this to my saved trials

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Updated: 10/8/2015
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Click here to add this to my saved trials

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Updated: 10/8/2015
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 10/8/2015
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Updated: 10/8/2015
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 10/8/2015
Click here to add this to my saved trials

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Updated: 10/8/2015
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 10/8/2015
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
Updated: 10/8/2015
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 10/8/2015
Click here to add this to my saved trials

Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
Updated: 10/8/2015
Improving the Quality of Advanced Cancer Care With Disease Management
Status: Enrolling
Updated: 10/8/2015
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
Updated: 10/8/2015
Improving the Quality of Advanced Cancer Care With Disease Management
Status: Enrolling
Updated: 10/8/2015
Click here to add this to my saved trials

Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
Updated: 10/8/2015
Isolation and Identification of Lung Cancer Precursor Cells From Malignant Pleural Effusion Specimens
Status: Enrolling
Updated: 10/8/2015
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
Updated: 10/8/2015
Isolation and Identification of Lung Cancer Precursor Cells From Malignant Pleural Effusion Specimens
Status: Enrolling
Updated: 10/8/2015
Click here to add this to my saved trials

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Click here to add this to my saved trials

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Click here to add this to my saved trials

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Click here to add this to my saved trials

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Click here to add this to my saved trials

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Updated: 10/13/2015
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
Click here to add this to my saved trials

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy
Updated: 10/15/2015
Phase II/Pharmacodynamic Study of the γ-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/15/2015
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy
Updated: 10/15/2015
Phase II/Pharmacodynamic Study of the γ-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/15/2015
Click here to add this to my saved trials

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Updated: 10/17/2015
A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Status: Enrolling
Updated: 10/17/2015
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Updated: 10/17/2015
A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Status: Enrolling
Updated: 10/17/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
Updated: 10/19/2015
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Click here to add this to my saved trials
